Clinical Trial Update: A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS) [Phase 3]

View source ↗

Summary

Phase 3 trial of diroximel fumarate in adults with relapsing forms of multiple sclerosis in the Asia-Pacific region has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Forms of Multiple Sclerosis

Drugs mentioned

• Diroximel Fumarate (diroximel fumarate)

Snippet

Sponsor: Biogen | Conditions: Relapsing Forms of Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2025-10-24